About Veracyte, Inc. 
Veracyte, Inc.
Pharmaceuticals & Biotechnology
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.
Company Coordinates 
Company Details
6000 Shoreline Ct Ste 300 , SOUTH SAN FRANCISCO CA : 94080-7606
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 87 Schemes (53.53%)
Foreign Institutions
Held by 147 Foreign Institutions (17.6%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Ms. Bonnie Anderson
Chairman of the Board, Chief Executive Officer
Mr. John Bishop
Lead Independent Director
Mr. Jens Holstein
Director
Dr. Frederick Cohen
Independent Director
Ms. Karin Eastham
Independent Director
Dr. Robert Epstein
Independent Director
Revenue and Profits:
Net Sales:
130 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
Pharmaceuticals & Biotechnology
USD 2,554 Million (Small Cap)
56.00
NA
0.00%
-0.26
4.10%
2.09






